The Top 5 Biosimilar Articles for the Week of February 22

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of February 22, 2021.

Number 5: Coherus BioSciences reported that the FDA has accepted for review its biologics license application (BLA) for an adalimumab biosimilar (CHS-1420), but did not specify the formulation concentration.

Number 4: Frontline use of rituximab biosimilars plus chemotherapy in patients with follicular lymphoma (FL) is more costly than a regimen of obinutuzumab (Gazyva) plus chemotherapy, investigators reported, based on a decision-analytic modeling study.

Number 3: Fresenius Kabi, a Germany-based biopharmaceutical company with global operations, mapped out an ambitious biosimilar launch program as it released earnings data.

Number 2: Fresenius Kabi has launched an adalimumab injectable biosimilar (Idacio) in Canada. The launch is the second adalimumab launch in a week, right after Sandoz’ launch of Hyrimoz.

Number 1: Gary H. Lyman, MD, PhD, provides an expert overview on overcoming the challenges of discussing biosimilars with patients.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Here are the top 5 biosimilar articles for the week of May 22, 2023.
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health
Here are the top 5 biosimilar articles for the week of May 15th, 2023.
Here are the top 5 biosimilar articles for the week of May 8, 2023.
andre harvin
Here are the top 5 biosimilar articles for the week of May 1, 2023.
Here are the top 5 biosimilar articles for the week of April 24, 2023.
Andre Harvin, PharmD
Here are the top 5 biosimilar articles for the week of April 17, 2023.
Here are the top 5 biosimilar articles for the week of April 10, 2023.
Related Content
© 2023 MJH Life Sciences

All rights reserved.